According to the Australian media outlet The Market Herald, Vitura Limited (ASX: VIT) has announced plans to offer a "smoke-free" solution, specifically a prescription e-cigarette. The capital city of Australia, Canberra, is pushing for e-cigarettes to be classified as prescription drugs, and Vitura sees this new regulation as a "market opportunity." As of the last trading session, the company's stock price was 25 cents.
Vitura company has swiftly responded to the newly implemented Canberra law this month which bans the sale of non-prescription e-cigarettes. Recognizing a "market opportunity," Vitura is preparing to become a prescription e-cigarette supplier. It plans to incorporate prescription e-cigarettes as a smoking cessation product on its online service platform, CanView.
For companies that have already ventured into the medical marijuana market without hesitation, including deals with prescription drug clinic providers and the mysterious field of psychedelic medicine, this move comes as no surprise. Today, Vitura Inc. provided a fair assessment of the reasons behind this decision.
In support of the recent and planned changes by the TGA, all nicotine vaping products (NVPs) will now only be available through medical prescriptions and can only be dispensed by pharmacists," Vitura company stated in a declaration. "Vitura has incorporated this innovative vertical product into its product supply and distribution ecosystem CanView.
A hidden loophole in the new federal law has paved the way for Vitura Corporation to make its mark in the prescription e-cigarette market. Doctors and nurse practitioners will now be able to prescribe e-cigarettes without seeking pre-approval from health regulatory agencies, thanks to the "Special Pre-Approval Scheme C Channel" review process.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
